NBSE — NeuBase Therapeutics Share News
0.000.00%
Last trade - 00:00NeuBase Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: NeuBase Therapeutics Files Prospectus Relates To Resale From Time To Time By Selling Stockholder Of Up To 308,635 Shares Of Common Stock
Brief: Neubase Therapeutics Demonstrates Functional Rescue In Myotonic Dystrophy Type 1 Model And Allele-Selective Inhibition Of Kras Mutations To Inhibit Tumor Growth
Brief: NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro As Chief Medical Officer
NeuBase Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Neubase Therapeutics Reports Financial Results For The Second Quarter Of Fiscal Year 2021
NeuBase Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: NeuBase Therapeutics Announces Pricing Of $40 Million Public Offering Of Common Stock
NeuBase Therapeutics slides on stock offering
Brief: Neubase Therapeutics Announces Proposed Public Offering Of Common Stock
Brief: Neubase Therapeutics Inc Files For Mixed Shelf Of Up To $250 Million
Brief: NeuBase Therapeutics Reports Financial Results For The First Quarter Of Fiscal Year 2021
Brief: NeuBase Announces Acquisition Of Gene Modulating Technology From Vera
NeuBase acquires gene technology assets from Vera, shares up
U.S. RESEARCH ROUNDUP-Gentherm, HMS Holdings, Paychex
Brief: Neubase Therapeutics Estimates Cash And Cash Equivalents Are Sufficient To Fund Currently Planned Operating & Capex Into Q1 Of Cy2022
U.S. STOCKS ON THE MOVE-Penumbra, NeuBase, Good Times Restaurants
NeuBase rises on positive data from muscular dystrophy treatment trial
Brief: Neubase Therapeutics Announces Positive Preclinical In Vivo Data For Patrol-Enabled Anti-Gene For The Treatment Of Myotonic Dystrophy Type 1